Source comparison
PT-141 vs Other Melanocortin Agonists: Response Comparison
The table below compares dose-response characteristics of PT-141 (bremelanotide) against two structurally related melanocortin peptides. Melanotan II (MT-II) and setmelanotide. Highlighting differences in receptor selectivity, efficacy plateau thresholds, and
This comparison does not assign a generated winner or score.
- The table below compares dose-response characteristics of PT-141 (bremelanotide) against two structurally related melanocortin peptides. Melanotan II (MT-II) and setmelanotide. Highlighting differences in receptor selectivity, efficacy plateau thresholds, and adverse event profiles that inform research protocol design.
- PT-141 (bremelanotide)
- 1.75mg SC
- MC4R > MC1R (10:1)
- 1.75mg. Higher doses show no added efficacy
- Nausea (40%), flushing (20%), transient hypertension (4.5%)
- Narrow therapeutic window. Doses above 1.75mg increase AE burden without improving primary endpoints; optimal for FSIAD research
- Melanotan II (MT-II)
- 0.5–1.0mg SC
- Non-selective (MC1R ≈ MC4R)
- 1.0mg. Effects plateau, side effects escalate
- Nausea (60–70%), skin darkening (universal), spontaneous erections
- Broader receptor activation drives higher AE rates; less suitable for controlled CNS research due to peripheral effects
- Setmelanotide
- 2.0–3.0mg SC daily
- Highly selective MC4R agonist
- 2.5mg daily. Dose-dependent weight loss without plateau
- Injection site reactions (40%), hyperpigmentation (25%), nausea (15%)
- Superior MC4R selectivity reduces nausea vs PT-141; approved for genetic obesity but not sexual dysfunction. Different therapeutic application
- PT-141's 10:1 MC4R-to-MC1R selectivity represents a middle ground between MT-II's non-selectivity and setmelanotide's high selectivity. This profile makes PT-141 effective for CNS-mediated sexual arousal research but limits its tolerability at higher doses compared to setmelanotide. MT-II, despite being the structural parent compound, produces unacceptable rates of nausea and universal skin pigmentation due to potent MC1R activation. Making it less viable for human research protocols despite its lower cost.